key: cord-0310195-zto39jla
authors: Trobajo-Sanmartin, C.; Miqueleiz, A.; Portillo, M. E.; Fernandez-Huerta, M.; Navascues, A.; Sola Sara, P.; Lopez Moreno, P.; R Ordonez, G.; Castilla, J.; Ezpeleta, C.
title: Emergence of SARS-CoV-2 variant B.1.575.2 containing the E484K mutation in the spike protein in Pamplona (Spain) May-June 2021
date: 2021-08-13
journal: nan
DOI: 10.1101/2021.08.11.21261950
sha: 4edc47c7dd04e1bbbeb474cc23ab77d3a259ca38
doc_id: 310195
cord_uid: zto39jla

With the emergence of new SARS-CoV-2 variants and the acquisition of novel mutations in exiting lineages, the need to implement methods capable of monitoring viral dynamics arises. We report the emergence and spread of a new SARS-CoV-2 variant within B.1.575 lineage containing the E484K mutation in the spike protein (named B.1.575.2) in a region of Northern Spain between May and June 2021. SARS-CoV-2 positive samples with cycle threshold value less than or equal to 30 were selected to screen of presumptive variants using the TaqPathTM COVID-19 RT-PCR kit and TaqManTM SARS-CoV-2 Mutation Panel. Confirmation of variants was performed by whole genome sequencing. Of the 200 samples belonging to the B.1.575 lineage, 194 (97%) corresponded to the B.1.575.2 sub-lineage, which was related to the presence of the E484K mutation. Of 197 cases registered in GISAID EpiCoV database as lineage B.1.575.2 194 (99.5%) were identified in Pamplona (Spain). This report emphasizes the importance of complementing surveillance of SARS-CoV-2 with sequencing for the rapid control of emerging viral variants.

During the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, 35 several variants were catalogued as variants of concern (VOC) and variants of interest specific concern because they present the spike mutation E484K, which has been 41 associated with the reduced neutralizing activity of antibodies and may be associated 42 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in CoV-2 cases that had acquired the E484K mutation (3,7). perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

The B.1.575.2 sub-lineage was predominant in Navarra since 99.5% (194/197 ) of the 115 cases registered in the GISAID EpiCoV database were identified in this region. By 116 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Screening PCR is a useful tool for detecting mutations, mainly because of its rapidity. 

Detection of R.1 lineage severe acute respiratory 162 syndrome coronavirus 2 (SARS-CoV-2) with spike protein

W152L/E484K/G769V mutations in Japan

Comparative Analysis of Emerging B.1.1.7+E484K SARS-CoV-2 168 isolates from Pennsylvania

European Centre for Disease Prevention and Control. Implications for the

EEA on the spread of the SARS-CoV-2 Delta (B.1.617.2) variant of 172 concern-23

Identification of SARS-CoV-2 176 spike mutations that attenuate monoclonal and serum antibody neutralization

Serum Neutralizing

Activity Elicited by mRNA-1273 Vaccine

Investigation of novel SARS-CoV-2 variant: Variant of 184 Concern 202012/01 (Technical briefing 5)

GISAID: Global initiative on sharing all influenza 189 data from vision to reality

All rights reserved. No reuse allowed without permission. perpetuity

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted

Nextstrain: real-time tracking of pathogen 193 evolution

A dynamic nomenclature proposal for SARS-CoV-2 lineages 197 to assist genomic epidemiology

and the Center for Viral Systems 203 Biology. outbreak.info

Personalized Virology Initiative 206 study group

SARS-CoV-2 spike E484K mutation reduces antibody 208 neutralisation. The Lancet

CoV-2 Variant of Interest (VOI) Harboring Mutation E484K in the Spike 217 Protein Was Identified within Lineage B.1.1.33 Circulating in Brazil

 139 The authors declare no conflict of interest. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Health with the European Regional Development Fund (COV20/00542).

Acknowledgements 145 We would like to thank the GISAID EpiCoV database and all contributing researchers 146 for making the genomes publicly available. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 13, 2021. ; https://doi.org/10.1101/2021.08.11.21261950 doi: medRxiv preprint 8 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 13, 2021. ; https://doi.org/10.1101/2021.08.11.21261950 doi: medRxiv preprint